NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. [electronic resource]
Producer: 20151021Description: 58-68 p. digitalISSN:- 1872-7980
- Animals
- Antineoplastic Agents, Alkylating -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Brain Neoplasms -- drug therapy
- Caspase 3 -- metabolism
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Dacarbazine -- analogs & derivatives
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- G1 Phase Cell Cycle Checkpoints -- drug effects
- Glioma -- drug therapy
- Humans
- Imidazoles -- pharmacology
- Inhibitory Concentration 50
- Male
- Mice, SCID
- Phosphatidylinositol 3-Kinase -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Phosphorylation
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-akt -- metabolism
- Quinolines -- pharmacology
- Signal Transduction -- drug effects
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Temozolomide
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
- bcl-2-Associated X Protein -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.